Valuation: Kamada Ltd.

Market Cap 1.52B 152B 505M 442M 415M 378M 710M 48.38B 711M 4.98B 1.92B 24.7B 1.9B 1.86B 79.62B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.52B 152B 505M 442M 415M 378M 710M 48.38B 711M 4.98B 1.92B 24.7B 1.9B 1.86B 79.62B EV / Sales 2026 *
2.51x
EV / Sales 2027 * 2.25x
Free-Float
54.68%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week+4.99%
Current month+7.35%
1 month+9.13%
3 months+24.12%
6 months-2.08%
Current year+16.37%
1 week 2,450
Extreme 2450
2,676
1 month 2,400
Extreme 2400
2,676
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 2015-06-30
Director of Finance/CFO 56 2017-12-30
Chief Operating Officer 54 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Exercice

VP Quality

61,323 0.1063%
9/14/26 Sell

Founder

-22,827 0.0396%
9/14/26 Exercice

General Counsel

23,459 0.0407%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+4.99%+14.65%+32.23% 504M
+0.72%+1.28%+35.80%-2.37% 79.7B
+5.56%+24.45%+623.30%+82.14% 69.04B
+1.36%+5.33%-8.90%-29.50% 60.82B
-0.78%-2.04%-11.65%+27.42% 47.16B
+0.66%+1.43%+5.02%+156.67% 46.38B
+2.87%+3.68%+58.15%-12.96% 32.37B
+1.83%+3.88%+46.69%+115.83% 25.27B
+0.68%+6.45%+12.00%+172.03% 22.72B
+1.04%0.00%+59.62%+105.60% 15.7B
Average +0.83%+3.67%+83.47%+64.71% 39.97B
Weighted average by Cap. +0.77%+4.22%+123.37%+50.89%

Financials

2026 *2027 *
Net sales 606M 60.59B 202M 176M 166M 151M 283M 19.31B 284M 1.99B 766M 9.86B 759M 742M 31.78B 673M 67.32B 224M 196M 184M 168M 315M 21.46B 315M 2.21B 852M 10.96B 843M 825M 35.32B
Net income 84.8M 8.48B 28.24M 24.68M 23.2M 21.14M 39.68M 2.7B 39.7M 278M 107M 1.38B 106M 104M 4.45B 104M 10.41B 34.67M 30.3M 28.48M 25.96M 48.72M 3.32B 48.75M 341M 132M 1.69B 130M 128M 5.46B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-09-22 ILA 2,630.00 -0.11% 131,704
26-09-17 ILA 2,633.00 +5.57% 129,318
26-09-16 ILA 2,494.00 +2.17% 114,135
26-09-15 ILA 2,441.00 -2.55% 101,220
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!